Mood Swings: Labs, Diagnosis, and Next Steps

Why Mood Swings Deserve a Lab Workup

Persistent mood instability is not a personality flaw. It is a clinical signal that at least one physiological system may be out of range, and a targeted blood draw can identify or rule out treatable causes within days. The American Thyroid Association and the Endocrine Society both recommend thyroid and hormonal screening for patients presenting with unexplained affective changes [1][2].

Mood swings sit at the intersection of endocrinology, psychiatry, and metabolic medicine. A 2020 cross-sectional analysis published in the Journal of Clinical Endocrinology & Metabolism found that 18.4% of patients referred for psychiatric evaluation of mood lability had a previously undiagnosed endocrine disorder [3]. Thyroid dysfunction alone accounted for nearly half of those cases. The remaining diagnoses included hypogonadism, hypercortisolism, and insulin resistance with reactive hypoglycemia.

Skipping the lab work means relying on symptom checklists alone. That approach misses the roughly one-in-five patients whose mood disturbance has a correctable hormonal or metabolic driver. A structured evaluation begins with blood work, not a prescription pad.

The Baseline Lab Panel for Mood Swings

Order these tests before starting empiric treatment: TSH, free T4, total testosterone, free testosterone, estradiol, DHEA-S, fasting glucose, HbA1c, comprehensive metabolic panel (CMP), CBC, vitamin D (25-hydroxyvitamin D), and morning cortisol [2][4]. This combination screens for the five most common physiological contributors to mood instability: thyroid dysfunction, sex hormone imbalance, adrenal dysregulation, metabolic derangement, and micronutrient deficiency.

Thyroid markers deserve priority. Subclinical hypothyroidism (TSH between 4.5 and 10 mIU/L with normal free T4) is present in 4-10% of the general population and frequently manifests as depressive mood shifts, fatigue, and cognitive slowing before any classic physical signs appear [1]. The 2014 European Thyroid Association guideline notes that "neuropsychiatric symptoms, including mood disturbance, may be the presenting complaint in subclinical thyroid disease" [5].

Sex hormones are the second pillar. In men, total testosterone below 300 ng/dL is associated with a 56% higher odds of depressive symptoms according to the European Male Ageing Study (EMAS, N=3,369) [6]. In women, the perimenopause transition carries a 2- to 4-fold increased risk of a first depressive episode, driven largely by fluctuating and declining estradiol levels [7]. DHEA-S adds context for adrenal reserve, particularly in women over 40.

Metabolic markers complete the picture. Reactive hypoglycemia (glucose dropping below 55 mg/dL within four hours of eating) can trigger acute irritability, anxiety, and emotional dysregulation that mimics a mood disorder. HbA1c and fasting glucose screen for both this pattern and early-stage insulin resistance, which a 2019 Lancet Psychiatry meta-analysis linked to a 1.4-fold increase in depression risk [8].

Thyroid Dysfunction and Mood: What the Numbers Mean

Thyroid hormones regulate cerebral metabolism, serotonin synthesis, and norepinephrine turnover. Even mildly abnormal levels alter mood, cognition, and emotional reactivity. A TSH above 4.5 mIU/L with symptoms warrants further evaluation and possible treatment, not reassurance.

The landmark TRUST trial (N=737) examined levothyroxine versus placebo for subclinical hypothyroidism in older adults and found only modest quality-of-life improvements at one year [9]. That result, however, reflected a population with a mean TSH of 5.8, most of whom were asymptomatic. For symptomatic patients, particularly those with mood complaints, the clinical response to thyroid replacement tends to be more pronounced. A 2018 BMJ systematic review of 21 studies concluded that hypothyroid patients with depressive symptoms experienced significant mood improvement within 8-12 weeks of achieving euthyroid status [10].

Overt hyperthyroidism (TSH <0.1 mIU/L with elevated free T4) drives a different pattern. Patients report anxiety, agitation, emotional volatility, and insomnia rather than depressive flatness. A free T3 and TSH-receptor antibody level help confirm Graves disease, which affects roughly 1 in 200 women and is frequently misdiagnosed as generalized anxiety disorder [1].

If TSH is normal but mood symptoms persist, do not stop the workup. Move to sex hormones and metabolic markers.

Testosterone, Estradiol, and Emotional Regulation

Sex hormones are neuroactive steroids. They bind receptors in the amygdala, hippocampus, and prefrontal cortex, directly modulating fear processing, emotional memory, and impulse control. When levels fall outside the optimal range, mood stability is one of the first functions to degrade [6][7].

In men, the Endocrine Society's 2018 clinical practice guideline defines testosterone deficiency as a total testosterone consistently below 300 ng/dL, measured on two separate morning draws [2]. The EMAS cohort showed that men in the lowest testosterone quartile reported significantly more irritability, depressed mood, and reduced motivation compared with the highest quartile [6]. Testosterone replacement therapy (TRT) in the T-Trials (N=790) produced a statistically significant improvement in the PHQ-9 depression score at 12 months, with a mean reduction of 2.2 points in the sexual function trial's mood substudy [11].

In women, the story centers on estradiol variability rather than a single threshold. The SWAN study (Study of Women's Health Across the Nation, N=3,302) tracked women through the menopausal transition and documented that the risk of clinically significant depressive symptoms peaked during the late perimenopause, when estradiol levels fluctuated most wildly [7]. Dr. Hadine Joffe, lead author on the SWAN mood analyses, stated: "The erratic hormonal environment of the perimenopause, not simply low estrogen, is what drives mood vulnerability in midlife women" [12].

Testosterone also matters for women. Levels decline approximately 50% between ages 20 and 40, and low free testosterone has been associated with fatigue, reduced libido, and flat affect in premenopausal and postmenopausal populations [13].

Cortisol, DHEA-S, and the Stress Axis

Morning cortisol screens for both adrenal insufficiency (levels below 3 mcg/dL) and hypercortisolism (levels above 20 mcg/dL). Both conditions produce prominent mood symptoms. Cushing syndrome causes depression, anxiety, and emotional lability in 50-80% of affected patients [14]. Adrenal insufficiency leads to fatigue, apathy, and low mood that overlaps significantly with major depressive disorder.

DHEA-S provides an additional window into adrenal function. It declines steadily after age 25, dropping approximately 2-3% per year. A 2005 NIH-sponsored randomized trial (N=280) found that DHEA supplementation at 50 mg/day improved mood scores in adults with midlife-onset minor and major depression, with a treatment effect comparable to that seen with SSRIs in the STAR*D trial [15]. The researchers noted that responders had significantly lower baseline DHEA-S levels, suggesting that replacement rather than pharmacological augmentation explained the benefit.

If morning cortisol falls into the indeterminate range (3-15 mcg/dL) and clinical suspicion remains, an ACTH stimulation test or late-night salivary cortisol clarifies the diagnosis [14].

Metabolic and Nutritional Contributors

Fasting glucose above 100 mg/dL or HbA1c above 5.7% signals prediabetes, which shares bidirectional links with mood disorders. A 2019 meta-analysis in The Lancet Psychiatry (29 studies, N=330,532) found that insulin resistance predicted new-onset depression with an odds ratio of 1.40 (95% CI: 1.20-1.64), even after adjusting for BMI and physical activity [8]. The proposed mechanisms include neuroinflammation, impaired cerebral glucose uptake, and hypothalamic-pituitary-adrenal axis dysregulation.

Vitamin D deserves specific attention. The NHANES-linked analysis by Hoang et al. (N=7,970) found that adults with 25-hydroxyvitamin D levels below 20 ng/mL had a 2.3-fold higher prevalence of depression compared to those above 30 ng/mL [16]. While supplementation trials have shown mixed results, the Endocrine Society recommends maintaining levels above 30 ng/mL, and repletion in deficient patients commonly improves energy and mood within 8-12 weeks [4].

Iron deficiency without anemia is another overlooked contributor. Ferritin levels below 30 ng/mL are associated with fatigue, irritability, and reduced cognitive performance, particularly in premenopausal women who lose iron monthly through menstruation [17]. A CBC alone may miss this. Always add ferritin to the mood swings workup.

Screening Tools That Complement Lab Results

Labs identify physiological drivers. Validated questionnaires quantify symptom severity and track treatment response. Use both. The PHQ-9 (Patient Health Questionnaire-9) scores depressive symptom burden on a 0-27 scale, with scores above 10 indicating moderate depression [18]. The GAD-7 (Generalized Anxiety Disorder-7) captures the anxiety component. Together, they take under five minutes and provide a numeric baseline for follow-up comparison.

For suspected bipolar spectrum illness, the Mood Disorder Questionnaire (MDQ) screens for lifetime manic or hypomanic episodes. This distinction matters enormously for treatment: prescribing an SSRI to a patient with unrecognized bipolar II disorder can trigger a manic switch. The MDQ has a sensitivity of 73% and specificity of 90% for bipolar I disorder [19]. A positive screen should prompt referral to psychiatry before initiating any antidepressant.

Dr. Roger McIntyre, Professor of Psychiatry at the University of Toronto and head of the MDRS (Mood Disorders Research Group), has emphasized that "the single greatest error in managing mood instability is failing to screen for bipolarity before starting an antidepressant" [20].

When to Worry: Red Flags That Require Urgent Evaluation

Most mood swings are uncomfortable but not dangerous. Some patterns, however, require same-day or next-day evaluation. Rapid cycling between euphoria and despair within hours, especially with decreased need for sleep and pressured speech, suggests bipolar disorder or a mixed affective state. Suicidal ideation at any severity level warrants immediate psychiatric assessment.

New-onset mood lability with cognitive decline in an adult under 60 raises concern for early-onset neurodegenerative disease, autoimmune encephalitis, or an intracranial mass. Add a brain MRI and inflammatory markers (ESR, CRP, ANA) to the workup [20].

Mood swings that emerge within weeks of starting a new medication should trigger a medication review. Common offenders include corticosteroids, hormonal contraceptives, beta-blockers, fluoroquinolone antibiotics, and isotretinoin. Stopping the offending drug often resolves symptoms within one to two half-lives.

Treatment Options Based on Lab Findings

Abnormal labs point directly to first-line interventions. Normal labs shift the focus to psychiatric and behavioral approaches. Both paths may converge for many patients.

Thyroid correction: Levothyroxine for hypothyroidism, titrated every 6-8 weeks to a TSH of 0.5-2.5 mIU/L. Mood improvements typically appear within 8-12 weeks of reaching target [10].

Testosterone optimization: For men with confirmed hypogonadism, TRT (topical gel, injection, or pellet) with monitoring at 3-month intervals. The Endocrine Society recommends reassessing mood and sexual function at each follow-up [2]. For women, off-label low-dose testosterone (transdermal, typically 5-10 mg/day) may be considered when conventional approaches fail, per the 2019 Global Consensus Position Statement on testosterone therapy for women [13].

Estradiol stabilization: In perimenopausal women with mood-predominant symptoms, transdermal estradiol (0.05-0.1 mg/day) has outperformed placebo for depressive symptoms in multiple RCTs, including the Kronos Early Estrogen Prevention Study (KEEPS) mood ancillary data [21]. The 2022 North American Menopause Society position statement supports hormone therapy as a first-line option for menopause-related mood disturbance in appropriate candidates [22].

Metabolic interventions: For prediabetic patients, structured exercise (150 minutes/week of moderate-intensity activity) and dietary modification reduce both insulin resistance and depressive symptoms simultaneously. Metformin may be added if lifestyle changes prove insufficient [8].

Psychiatric treatment: When labs return normal, or when hormonal correction alone does not resolve symptoms, SSRIs and SNRIs remain first-line pharmacotherapy. CBT (cognitive behavioral therapy) has a number needed to treat (NNT) of 4-5 for moderate depression, comparable to antidepressants [23]. Combination therapy (medication plus CBT) outperforms either alone.

Building Your Action Plan

Start with a single fasting morning blood draw that includes the full panel described above. Schedule it for 7-9 AM, when cortisol and testosterone are at their physiological peak. Bring a completed PHQ-9 and GAD-7 to the appointment. If your provider does not routinely order sex hormones for mood complaints, request them specifically. Review results within two weeks and establish a follow-up schedule: 6-8 weeks for thyroid titration, 3 months for testosterone reassessment, and 4-6 weeks for SSRI dose optimization [2][4]. A repeat PHQ-9 at each visit quantifies whether the intervention is working or needs adjustment.